NEWS
Indian CDMOs form trade group
At CPHI in Milan in October , eight Indian CDMOs announced that they have formed a trade group to raise the profile of India ’ s drug services sector and make it a destination of choice . “ We are trying to advocate the idea that , like IT services , pharma services could be a big industry in India ,” said Aragen CEO Manni Kantipudi ( pictured ), who leads the group .
One key goal is to streamline the regulatory process the Indian drug authorities impose . At present , it typically takes around six weeks to obtain permission to start a project in India , compared to one week in China .
The partners also hope to improve India ’ s skills capacity to support the development of innovator drugs as well as generics , where India currently excels . It will work with academic institutes to train chemists for CDMO work , and bridge the numbers gap with China . At present , Kantipudi noted , the eight members employ about 8,000 chemists against around 25,000 at WuXi AppTec alone .
CONTRACT COATING AND IMPREGNATION
Exwold is a market leader in coating and impregnation for the speciality and crop market , with over 30 years of unrivalled expertise .
WHY EXWOLD IS INDUSTRY ’ S PARTNER OF CHOICE
• Three drum blenders provide gentle mixing to maintain the carrier integrity .
• Each is fitted with spray bars to spray the active at the specified concentration .
• Highly viscous actives can be heated and applied .
FOR SUSTAINABLE AND CONFIDENTIAL SOLUTIONS
ENQUIRIES @ EXWOLD . COM + 44 ( 0 ) 1429 230340
• Coating and Impregnation
• Blending
• Extrusion
• Pan Granulation
• Other co-formulants can be added , ensuring the delivery of your unique formulation .
• Product can be sieved to meet your precise particle size requirements .
• We can pack into bulk bags , or directly into your chosen pack size .
• We have capacity from 1 to 1000s of tonnes per annum .
Olon acquires HuvePharma
Italian CDMO and API producer Olon Group has acquired its compatriot HuvePharma Italia , which makes APIs and advanced intermediates via chemical synthesis , from the Huvepharma EOOD group . This is described as part of Olon ’ s strategy of growth , consolidation and expansion , both internally and through acquisitions . Terms were not disclosed .
The company said that this means a “ significant increase in its total production capacity ” and makes it one of the biggest CDMOs in Europe . Huvepharma ’ s site at Garessio , which was owned by Sanofi until 2016 , brings the combined total to
13 , including nine in Italy , with total reaction capacity of 3,250 m 3 .
Olon added that the acquisition plan “ involves a complete operational integration ” of Huvepharma ’ s facilities , workforce and portfolio and “ a plan to revive the production potential of the Garessio plant and , through the development of new business opportunities , bring it to full production capacity ”. Half of its production lines are fully automated and it has in recent years developed the production of an antimalarial through advanced photo-oxidation technology and nanoparticles .
This follows the July acquisition of GTP Bioways Group , a French biotech CDMO offering R & D services , process development and production of monoclonal antiodies , enzymes , proteins , nanodrugs , antibody-drug conjgates ( ADCs ) and fill-finish . GTP Bioways is being integrated into the Olon Biotech division .
During Q3 , Olon also finalised its € 25 million investment in a facility to make ultra high potency APIs , payloads and payloadlinkers for ADCs under extremely high containment . This and the acquisition of GTP Bioways will enable Olon Biotech to offer full services for the development and production of ADCs .
SEP / OCT 2024 SPECCHEMONLINE . COM
15